Abstract

Opioids targeting \(\mu\) receptors produce analgesia in the peri-operative period and palliative care. They also produce side effects including respiratory depression, tolerance/dependence and addiction. The N/OFQ opioid receptor (NOP) also produces analgesia but is devoid of the major MOP side effects. Evidence exists for MOP-NOP interaction and mixed MOP-NOP ligands produce analgesia with reduced side effects. We have generated a HEK\(_{\text{MOP/NOP}}\) human expression system and used bivalent MOP-NOP and fluorescent ligands to (i) probe for receptor interaction and (ii) consequences of that interaction. We used HEK\(_{\text{MOP/NOP}}\) cells and two bivalent ligands; Dermorphin-N/OFQ (MOP agonist-NOP agonist; DeNO) and Dermorphin-UFP101 (MOP agonist-NOP antagonist; De101). We have determined receptor binding profiles, GTP\(_{\gamma}\)\([^{35}\text{S]}\) binding, cAMP formation and ERK1/2 activation. We have also probed MOP and NOP receptor interactions in HEK cells and hippocampal neurones using the novel MOP fluorescent ligand, Dermorphin\(_{\text{ATTO488}}\) and the NOP fluorescent ligand N/OFQ\(_{\text{ATTO594}}\). In HEK\(_{\text{MOP/NOP}}\) MOP ligands displaced NOP binding and NOP ligands displaced MOP binding. Using fluorescent probes in HEK\(_{\text{MOP/NOP}}\) cells we demonstrated MOP-NOP probe overlap and a FRET signal indicating co-localisation. MOP-NOP were also co-localised in hippocampal tissue. In GTP\(_{\gamma}\)\([^{35}\text{S]}\) and cAMP assays NOP stimulation shifted the response to MOP rightwards. At ERK1/2 the response to bivalent ligands generally peaked later. We provide evidence for MOP-NOP interaction in recombinant and native tissue. NOP activation reduces responsiveness of MOP activation; this was shown with conventional and bivalent ligands.
Introduction

Opioids targeting the mu opioid peptide (MOP) receptor are amongst the most widely used analgesics in both acute and chronic pain treatment. However, exclusively targeting this receptor leads to addiction and/or tolerance. More interestingly, animal studies demonstrated that co-targeting an additional member of the opioid receptor family with either agonists or antagonists has been shown to be beneficial in longer-term antinociceptive paradigms, while reducing tolerance [1]. This synergistic effect is believed to be derived from the ability of opioid receptors to interact at a molecular and structural level [2]. The dimerisation of opioid receptors has been shown to influence receptor trafficking, signalling and the ability to inhibit or delay tolerance and dependence/addiction [3–5]. With regards to heterodimeric pairings, the majority of work in this field has been based on the association between MOP and delta opioid peptide (DOP) receptors [6–13]. There is growing evidence to suggest that the potential pairing of the MOP and nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor systems may be beneficial in developing analgesics with reduced side effects [14–17].

NOP is a “non-classical” opioid receptor lacking affinity for the opioid antagonist naloxone [18] and with little or no affinity for the classical endogenous opioid peptides. The NOP receptors endogenous ligand N/OFQ has no affinity for classical opioid receptors [19]. Initial studies in rodents indicated that the NOP-N/OFQ system was pronociceptive when administered supraspinally and antinociceptive when administered spinally, however recent work in non-human primates (NHP) has shown these effects to be species dependent, with N/OFQ providing potent analgesia at both sites [20–23].

Evidence linking MOP-NOP is supported from in vitro experiments to in vivo work with NHP demonstrating the synergistic effect N/OFQ has on morphine administration [24]. The most recent work spanning both in vivo and in vitro studies centres on the development of a mixed MOP-NOP ligand, cebranopadol. Cebranopadol has a favourable safety profile in preclinical studies [17]. This complements data with MOP-NOP ligands BU08028 [25] and AT-121 [26]. Cebranopadol is being evaluated in clinical trials [27–29].

The co-operative effect seen in the dual targeting of MOP and NOP could be due to a number of factors, including the formation of MOP/NOP heterodimers, with this action being supported by the co-localisation of MOP and NOP throughout the pain pathway [30–32]. While work remains to demonstrate evidence of MOP-NOP heterodimerisation in vivo, in vitro studies suggest heterodimerisation. An elegant study by Evans et al., using tagged receptors, demonstrated the co-localisation of NOP and MOP (as well as DOP and KOP receptors) [33]. Treatment of these co-expressing cell lines with N/OFQ demonstrated co-internalisation of both the classical opioid receptor and the NOP receptor indicating their structural linkage [33]. Work in CHO cells demonstrated co-immunoprecipitation of NOP and MOP opioid receptors, as well as the ability of classical opioid ligands to displace $[^3]$H-N/OFQ, which does not occur in single expression systems [34]. Heterodimerisation of MOP and NOP has also been shown to negatively impact MOP cell signalling [35] but can lead to an improved side effect profile, as noted by heterodimerisation of the truncated 6TM MOP receptor to NOP [36].

Previous work from our group has identified a novel bivalent ligand, Dermorphin-Nociceptin/Orphanin FQ (DeNO) [15] that functions as an agonist at both MOP and NOP. To further understand the role NOP may play in MOP receptor signalling, we have synthesised a novel MOP agonist (Dermorphin)-NOP antagonist (UFP-101) bivalent ligand (De101). As with DeNO, the MOP agonist chosen was Dermorphin. UFP-101 ([Nphe$^1$,Arg$^{14}$,Lys$^{15}$]N/OFQ-NH$_2$), is an antagonist analogue of N/OFQ designed to display improved affinity and duration of action in vivo [37]. UFP-101 displays high affinity for the NOP receptor (pK$_i$ of 10.14) with an antagonist pA$_2$ value in the range 8.4–9 [38].
While the effects of selective peptide agonists, such as DAMGO and N/OFQ [5,10,33,35], have been studied in co-expression systems, very little evidence exists demonstrating the activity of mixed ligands in a co-expression system. In order to assess the cellular aspects of mixed ligand interactions in a system co-expressing MOP and NOP, we have developed a human HEK co-expression system (HEK\textsubscript{MOP/NOP}). We have used the bivalent MOP/NOP full agonist DeNo (15), in conjunction with the newly synthesised De101. De101 is a counterpoint to the ligand DeNO (S4 Fig in S1 File). Binding and functional activity assays were performed to determine the suitability of De101 as a test ligand. Furthermore, we visualised and determined co-expression using two novel fluorescent ligands, N/OFQ\textsubscript{ATTO594} [14] for NOP and Dermorphin\textsubscript{ATTO488} for MOP [39]. These imaging experiments were performed both using HEK\textsubscript{MOP/NOP} and mouse CA1 hippocampal neurons to determine the potential for receptor co-localisation \textit{Ex Vivo}. Mouse CA1 hippocampal neurones have been shown to express both MOP [40] and NOP receptors [41], however colocalisation/coexpression has not yet been definitively proven.

We hypothesise that co-expression of MOP and NOP will lead to measurable changes in downstream signalling pathways, such as GTP\textsubscript{$\gamma$}[\textsuperscript{35}S] binding and cAMP inhibition, as well as changes in the activation of the mitogen-activated protein kinase, ERK1/2.

**Materials and methods**

**Materials**

Dermorphin, N/OFQ, UFP-101, DeNO, De101, N/OFQ\textsubscript{ATTO594} and Dermorphin\textsubscript{ATTO488} were synthesised in house (University of Ferrara). Tritiated N/OFQ ([\textsuperscript{3}H]-N/OFQ), tritiated diprenorphine ([\textsuperscript{3}H]-DPN), GTP\textsubscript{$\gamma$}[\textsuperscript{35}S] and [\textsuperscript{3}H]-cyclic adenosine monophosphate ([\textsuperscript{3}H]-cAMP) were purchased from Perkin Elmer (UK). Naloxone-HCl, cyclic adenosine monophosphate (cAMP), GTP\textsubscript{$\gamma$}S were purchased from Sigma-Aldrich (U.K). Phospho-ERK1/2 [42], vinculin [43] and Anti-NeuN [44] primary antibodies were purchased from Cell Signalling Technologies (U.S.A). All cell culture products were purchased from Thermofisher Scientific (UK). AbDelivirin” purchased from OZ Bioscience (Australia), anti-rabbit secondary conjugated to Alexa-405 [45] was purchased from Abcam (U.K). All other reagents were of the highest purity available. CHO\textsubscript{MOP/DOP/KOP/NOP} cells were a gift from T Costa (Istituto Superiore di Sanita, Rome, Italy).

**Cell culture**

Chinese hamster ovary (CHO) cells expressing recombinant human opioid receptors were cultured in either Hams F12 (for classical opioid receptors) or DMEM/Hams F12 1:1 (for CHO-NOP cells). The media contained 10% fetal bovine serum, 100 IU ml\textsuperscript{-1} penicillin, 100 \mu g ml\textsuperscript{-1} streptomycin and 2.5 \mu g ml\textsuperscript{-1} fungizone. Stock cultures were maintained through the addition of 200 \mu g ml\textsuperscript{-1} G418 (for CHO\textsubscript{MOP}, CHO\textsubscript{DOP} and CHO\textsubscript{KOP} cells). CHO\textsubscript{NOP} cells were maintained with G418 (200 \mu g ml\textsuperscript{-1}) and hygromycin B (200 \mu g ml\textsuperscript{-1}). Human embryonic kidney (HEK) cells expressing the recombinant human opioid receptors were grown in MEM containing 100 \mu g ml\textsuperscript{-1} streptomycin, 2.5 \mu g ml\textsuperscript{-1} fungizone, 100 IU ml\textsuperscript{-1} penicillin and 10% foetal bovine serum. G418 (400 \mu g ml\textsuperscript{-1}) was used to maintain cells expressing human MOP receptors, with hygromycin B (400 \mu g ml\textsuperscript{-1}) used for cells expressing recombinant NOP receptors. For the cells co-expressing MOP and NOP, a combination of G418 (400 \mu g ml\textsuperscript{-1}) and hygromycin B (200 \mu g ml\textsuperscript{-1}) was used. A temperature of 37˚C was used to maintain cell cultures in 5% CO\textsubscript{2}/humidified air. Cells were used for experiments upon reaching confluency as in [15].
Development of Co-expression system

Plasmids containing cDNA clones for human MOP or human NOP receptors were purchased from cDNA Resource Centre (www.cdna.org). Clones were individually transfected into HEK293 cells using Fugene HD (Promega, UK). Cell lines stably expressing the MOP receptor or NOP receptor were selected by adding geneticin (800 μg/ml for MOP) or hygromycin B (600 μg/ml for NOP) to cell culture medium. Following selection of preferred HEK MOP single expression clone, cells were co-transfected with NOP, with co-expression selected by co-administering geneticin (400 μg.ml⁻¹) and hygromycin B (200 μg.ml⁻¹). Surface expression of receptors for the single and co-expression systems was determined by using radioligand binding assays as described below (further cloning details can be found in Supplement section 1 in S1 File).

Synthesis of De101

The MOP/NOP ligand De101 was synthesized using a classical thiol-Michael reaction following the experimental conditions previously reported for the synthesis of DeNo using [Cys¹⁸]UFP-101 in place of [Cys¹⁸]N/OFQ-NH₂. Structure and Chemistry can be found in S4-S6 Figs in S1 File.

Membrane preparation

CHO opioid or HEK opioid cells were harvested, homogenised and resulting membrane fragments resuspended in wash buffer (50 mM Tris-HCl and 5 mM MgSO₄, pH 7.4 with KOH) for saturation and displacement assays or a homogenisation buffer (50 mM HEPES and 1 mM EDTA, pH 7.4 with NaOH) for GTPγ³⁵S functional assays. Membrane suspensions were sedimented at 20,374g for 10 minutes at 4°C, with the process being repeated three times. The pellet was suspended in the appropriate buffer at the desired volume before protein concentration was measured using a Lowry assay [15,46].

Radioligand binding assays

In Saturation binding assays, a range of concentrations of [³H]-DPN (HEK MOP or HEK MOP/NOP) or [³H]-N/OFQ (HEK NOP or HEK MOP/NOP) were incubated with membrane protein (40 μg) in a Tris-HCl based buffer (0.5ml of 50 mM Tris, 0.5% BSA, pH 7.4). Non-specific binding was determined by using 10 μM naloxone and/or 1 μM N/OFQ.

For displacement binding assays, membrane protein (40 μg) was incubated in 0.5ml of 50 mM Tris, 0.5% BSA and ~0.8nM [³H]-DPN (CHO opioid/KOP, HEK MOP or HEK MOP/NOP) or ~0.8nM [³H]-N/OFQ (HEK NOP or HEK MOP/NOP) along with varying concentrations (10 μM-1pM) of the test ligands. Non-specific binding was determined using 10μM naloxone and/or 1μM N/OFQ.

In both saturation binding and displacement binding studies, samples were incubated for 1 hr at room temperature before reactions were terminated by vacuum filtration onto polyethyleneimine (PEI) soaked Whatman-GF/B filters, using a Brandel Harvester [14].

GTPγ³⁵S assays

In GTPγ³⁵S functional assays, 25μg of membrane protein was incubated in 50 mM HEPES, 1 mM EDTA, 1 mM DTT, 5 mM MgCl₂, 100 mM NaCl 0.1% BSA, 0.15 mM bacitracin; pH 7.4, GDP (33 μM), and ~ 150 pM GTPγ³⁵S. Varying concentrations (10 μM-1pM) of the test ligands were added prior to incubation. Unlabelled GTPγS (10 μM) was used to determine non-specific binding. The samples were incubated for 1hr at 30°C with gentle agitation,
following which, reactions were terminated by vacuum filtration through Whatman-GF/B filters (without PEI), using a Brandel harvester [15].

**Cyclic adenosine monophosphate inhibition assays**

HEK$_\text{MOP}$, HEK$_\text{NOP}$ or HEK$_\text{MOP/NOP}$ cells were suspended in Krebs/HEPES buffer, containing isobutylmethylxanthine (1mM) and forskolin (1μM) as appropriate. Varying concentrations (0.1pM-1μM) of the test ligands were added prior to incubation. Following a 15 minute incubation at 37˚C, the reaction was terminated by addition of 10M HCl, following which 10M NaOH and Tris-HCl (1M, pH7.4) were added to neutralise the reaction followed by centrifugation (13,000g, 2 min). Binding protein from bovine adrenal cortex was used to measure cAMP collected from the supernatant as in [47].

**ERK 1/2 phosphorylation assays**

Western blotting was used to determine ERK1/2 activity in HEK$_\text{MOP}$, HEK$_\text{NOP}$ or HEK$_\text{MOP/NOP}$ cells. Cells were serum starved for 24 hours prior to treatment with the test ligands. Media was removed after 24 hours and replaced with Krebs/HEPES buffer. All test ligands were delivered at a concentration of 1μM. Ligands were added at appropriate time points (2.5; 5; 7.5; 10; 15; 20 and 30 minute intervals), following which the assay was terminated by removal of Krebs/HEPES and addition of lysis buffer (Tris-HCl (pH 7.4), 20 mM; 1% (vol/vol); Triton X-100, 10% (vol/vol); glycerol, NaCl, 137 mM; EDTA, 2 mM; β-glycerophosphate, 25 mM; sodium orthovanadate; 1 mM; phenylmethanesulfonylfluoride, 500μM; leupeptin, 0.1 mg/ml; benzamidine, 0.2 mg/ml; pepstatin, 0.1 mg/ml). Cell wells were scraped, the lysis buffer collected and centrifuged at 17,000g at 0˚C for 10 minutes.

The supernatant was removed and added to an equal volume of Laemmlli buffer (100mM Tris-HCl (pH 6.8), 2% SDS, 10% Glycerol, 0.1% Bromophenol Blue). Samples were denatured (100˚C for 5 minutes) and separated by 10% SDS-PAGE, followed by transfer onto nitrocellulose paper by wet transfer (39mM glycine, 48mM Tris-Base, 0.037%w/v SDS, 20% methanol). Membranes were blocked in 5% milk TBS-T ([50 mm Tris-base, 150 mm NaCl, 0.1% Tween-20 (vol/vol), pH 7.5 NaOH) solution for 1 hr at room temperature under gentle agitation. Membranes were washed 3 times in TBS-T, following which the membranes were incubated in primary phospho-ERK1/2 antibodies (1:6000 dilution) diluted in TBS-T overnight at 4˚C. Following 3 washes in TBS-T, membranes were incubated in horseradish peroxidase-conjugated secondary antibodies (1 hr room temperature; 1:1000 dilution 5% milk/TBS-T solution). Chemiluminescence detection, using the ChemiDoc™ MP imaging system (Bio-Rad, UK) was used to visualise immune-reactive bands.

In order to probe for loading controls, membranes were stripped using Restore Plus™ (ThermoFisher, UK) for 15 minutes. Membranes were thoroughly washed in TBS-T and blocked using the 5% milk/TBS-T for 1 hr at room temperature. Membranes were again probed overnight at 4˚C, using ERK1/2 (total) antibody (1:3000 dilution in TBS-T) following which detection of the immune-reactive band was achieved as previously described. Normalisation of total protein levels was achieved by representing levels of phosphor-ERK1/2 as a proportion of total ERK1/2 protein [15].

**Mouse hippocampal brain slices**

This study was conducted in accordance with the UK Animals Scientific Procedures Act, 1986 and following approval by the animal welfare and ethics committee of the University of Leicester. Pregnant C57/BL6 mice, at stage between E11-E13, were obtained from Charles River UK and delivered in house. Hippocampal slices were prepared from male and female C57/BL6
mouse pups aged between postnatal day (P) 6 to 9. Mice were housed in a 12 hour light/dark cycle and food and water was given ad libitum. Mice were humanely killed in accordance with home office guidelines by schedule 1 using cervical dislocation followed by swift decapitation. Hippocampal slices were prepared by the methods denoted in [48], with further modifications to promote neural outgrowths. Dissection buffer (DB) utilised for dissections consisted of HBSS (Hank balanced salt solution), 4.5mg/ml glucose and 3.75μg/ml of amphotericin B. Culture media contained 50% MEM, (minimal essential medium), 25% HBSS, 25% heat inactivated horse serum, 4.5mg/ml glucose, 3.75μg/ml of amphotericin B and 0.5 mM glutamine. Following dissection, brains were transferred to a sterile petri dish on ice containing ice cold DB. After separation of the hemispheres with a scalpel, the hippocampi were isolated whilst the tissue was fully submerged in ice cold DB. Transverse hippocampal slices at 350μm were prepared using a tissue chopper (Mcllwain tissue chopper). Using sterile syringe needles, slices were carefully separated and transferred into 6 well plates containing 28mm Menzel glaser #1-coverslips (Thermos Scientific, UK) with the prior addition of Celltak™ (1μg.mL1) (Sigma, UK). This promotes adhesion of slices and neuronal outgrowth. Slices were submerged in 1ml of pre-warmed media. Plates were placed in a humidified incubator at 37˚C and perfused with 95% O₂ and 5%CO₂ for a minimum of one week prior to inspection for neuronal outgrowths. Culture media was topped up every 2–3 days. Twenty-four hours prior to experimental use, cells were treated with a complex containing anti-Neun Ab attached to an anti-rabbit Alexa-fluor 405nm secondary Ab (UK) coated in 10μL Ab-Delivirin™ to allow identification and visualisation of neuronal cells [41].

**Confocal microscopy**

Confuent HEK MOP, HEK NOP and HEK MOP/NOP cells (and hippocampal slices) were grown on ethanol-sterilised coverslips (28mm Menzel glaser #1), incubated for 24h before being transferred to a Harvard PDMI-2 peltier unit and continually perfused with ice-cold Krebs buffer, pH 7.4, maintaining a constant temperature of 4˚C.

N/OFQ ATTO594 and Derm ATTO488 were injected either separately or together at a concentration of 100nM following which images were acquired using a Nikon C1Si confocal microscope (60X oil immersion objective). N/OFQ ATTO594 (excitation 594 nm; emission 620 nm), and/or Derm ATTO488 (excitation 488 nm; emission 520 nm) were allowed to incubate for 5 min, before coverslips were washed with the ice-cold Krebs. Following wash-off, cells were imaged at the desired wavelength (Derm ATTO488: 488nm, image capture at 520 nm; N/OFQ ATTO594: 594 nm, image captured at 620nm), with the images collected by Nikon C1Si software [14,39]. As both probes are agonists all experiments were undertaken at 4˚C to prevent receptor activation and internalisation.

FRET studies were undertaken by measuring the binding of both 100nM Derm ATTO488 and 100nM N/OFQ ATTO594 on HEK MOP/NOP cells. Derm ATTO488 was stimulated by the 488nm laser (laser power: 20%; Gain: 6.85) with measurements assessed in both the green and red channel [49]. To confirm FRET-pairing, several controls were undertaken (see Fig 7). N/OFQ ATTO594 was incubated on HEK MOP/NOP cells alone and measured with the 488 nm laser, while photobleaching of N/OFQ ATTO594 was undertaken using 594nm laser (laser power: 50% Gain: 7.10) in the presence of Derm ATTO594 to measure its relative fluorescence pre and post photobleaching [50]. All FRET experiments were undertaken at 4˚C to prevent receptor activation and internalisation.

**Statistical analysis**

For radioligand assays and Western blot techniques all data are expressed as the mean ± SEM (n). GraphPad Prism V6.05 (San Diego, USA) was used for curve fitting and analysis. For
displacement binding studies, the concentration which caused 50% displacement of the radioligand (IC$_{50}$) was corrected for the competing mass of radioligand by use of the Cheng and Prusoff equation using the pK$_d$ values produced from saturation binding experiments (S2, S4 and S6 Tables in S1 File) [51]. GTP$_{\gamma}$[35S] binding results are expressed as a stimulation factor (agonist stimulated specific binding/basal specific binding) [15]. In cAMP inhibition studies, results are expressed as percentage inhibition of forskolin stimulation. For ERK1/2 activity, following normalisation of the protein bands, ERK1/2 activity is measured as activity compared to basal levels. Statistical analysis was performed using t-test or one way ANOVA with Bonferroni correction, as described in figure and table legends. For Confocal microscopy, FIJI was used to analyse colocalization using the Ezcolocalization plugin to determine Pearson correlation coefficient [52]. This software measures relative overlapping fluorescence intensities to produce statistical data (Pearson coefficient correlation) to determine levels of co-expression. Changes in fluorescence during photobleaching experiments was measured as previously described using corrected total cell fluorescence [Corrected total cell fluorescence = Integrated density – (Area of selected cell × Mean fluorescence of background readings)] [53].

Results
Characterisation of De101

In displacement binding studies at CHO$_{hMOP}$, Dermorphin and De101 displaced the binding of [3H]-DPN in a concentration dependent and saturable manner (Table 1 and Fig 1). De101 (9.64) demonstrated a significant increase in affinity at MOP, when compared to the parent compound Dermorphin (8.69). At CHO$_{NOP}$, De101 displaced [3H]UFP-101 in a concentration dependent and saturable manner. De101 (10.08) displayed similar pK$_i$ values, for NOP, to the reference compounds N/OFQ (10.69) and UFP-101 (10.08).

At CHO$_{DOP}$, De101 (7.95) demonstrated an increase in affinity compared to its parent compounds. Dermorphin displayed an affinity of 7.17, while UFP-101 failed to displace [3H]-DPN at the DOP receptor. Furthermore, De101 (7.61) showed affinity for the KOP receptor, whereas the parent compounds (Dermorphin and UFP-101) failed to displace [3H]-DPN at this receptor.

Dermorphin and De101 stimulated the binding of GTP$_{\gamma}$[35S] in a concentration dependent and saturable manner at the MOP receptor (Fig 2A). De101 (2.71) demonstrated similar maximal responses to that of Dermorphin (2.63). The pEC$_{50}$ value for De101 (8.02) showed no significant difference to that of the parent compound, Dermorphin (7.83).

At CHO$_{NOP}$, N/OFQ, UFP-101 and De101 stimulated the binding of GTP$_{\gamma}$[35S] in a concentration dependent and saturable manner (Fig 2B). De101 (1.31) demonstrated an $E_{\text{max}}$

|               | CHO$_{MOP}$ | CHO$_{NOP}$ | CHO$_{DOP}$ | CHO$_{KOP}$ |
|---------------|------------|-------------|-------------|-------------|
| Reference ligand | -          | -           | 10.02 (±0.26) | 10.16 (±0.02) |
| Dermorphin    | 8.69 (±0.10) | <5          | 7.17 (±0.11) | <5          |
| N/OFQ         | <5         | 10.69 (±0.10) | <5          | <5          |
| UFP-101       | <5         | 9.87 (±0.10)  | <5          | <5          |
| DeNO          | 9.55 (±0.10)* | 10.22 (±0.09) | 8.12 (±0.11)* | 7.34 (±0.13)* |
| De101         | 9.64 (±0.13)* | 10.08 (±0.08) | 7.95 (±0.13)* | 7.61 (±0.06)* |

Data are displayed as mean (±SEM) of n≥5 experiments. Statistical significance (*) demonstrates p<0.05, using one-way ANOVA with Bonferroni corrections, when compared to the reference ligands: Dermorphin (MOP), N/OFQ (NOP), Naltrindole (DOP) and Dynorphin-A (KOP).

https://doi.org/10.1371/journal.pone.0260880.t001
Fig 1. Displacement of [³H]-DPN by Dermorphin and De101 and reference ligands at (A) CHO₅OP, (B) CHO₆OP, (C) CHO₇OP and the displacement of [³H]UFP-101 by De101 and N/OFQ at (D) CHO₈OP cell membranes. Data are the mean (±SEM) of n = 5 experiments. DeNO curves are replicated from previous studies [14]. Reference ligands: Dermorphin; Naltrindole; Dynorphin-A; N/OFQ, (Nociceptin/Orphanin FQ).

Fig 2. A) Ligand stimulated GTPγ³⁵S binding by Dermorphin and De101 are shown in CHO₅OP cell membranes. B) Ligand stimulated GTPγ³⁵S binding by N/OFQ, UFP-101 and De101 are shown in CHO₆OP cell membranes. DeNO curves are replicated from previous studies [14]. Data are the mean (±SEM) of n = 5 experiments.
similar to that of UFP-101 (1.42). Furthermore, De101 (8.11) demonstrated a similar pEC_{50} to that of its parent compound, UFP-101 (8.23).

**Characterisation of Ligands in the co-expression system**

**Saturation binding assays.** In saturation binding studies, both HEK\textsubscript{MOP} (B\textsubscript{max}: 1542\pm35; pK\\textsubscript{d}: 9.26\pm0.05 using \textsuperscript{3}H-DPN) and HEK\textsubscript{NOP} (B\textsubscript{max}: 887\pm93; pK\\textsubscript{d}: 9.50\pm0.09 using \textsuperscript{3}H-N/OFQ) demonstrated binding for their respective radioligands (with non-specific binding determined by naloxone for MOP or N/OFQ for NOP) (Fig 3). Neither Tritiated-DPN nor \textsuperscript{3}H-N/OFQ were able to bind to HEK\textsubscript{NOP} or HEK\textsubscript{MOP} respectively (Fig 3A and 3B).

In HEK\textsubscript{MOP/NOP} cells, both \textsuperscript{3}H-DPN and \textsuperscript{3}H-N/OFQ were able to bind and both were displaced by naloxone, N/OFQ or a combination of both (Fig 3C and 3D). Tritiated-DPN, in combination with naloxone, produced a B\textsubscript{max} of 464 and pK\\textsubscript{d} of 8.72. Tritiated-DPN, with N/OFQ as the NSB, produced a B\textsubscript{max} of 169 and pK\\textsubscript{d} of 8.59. When using \textsuperscript{3}H-N/OFQ and N/OFQ to determine non-specific binding, a B\textsubscript{max} of 689 and pK\\textsubscript{d} of 9.51 was produced. Tritiated-N/OFQ, with naloxone as NSB, produced a B\textsubscript{max} of 228 and pK\\textsubscript{d} of 10.05. Cross-displacement, in terms of NSB determination, suggests an interaction; this was probed further in a series of displacement experiments.

**Displacement binding assays.** Dermorphin displaced \textsuperscript{3}H-DPN in HEK\textsubscript{MOP} cells (pK\\textsubscript{i}: 8.32) and in HEK\textsubscript{MOP/NOP} cells (pK\\textsubscript{i}: 7.86), with a small (but not statistically significant)
reduction in affinity (Fig 4 and Table 2). Dermorphin was unable to displace \(^{3}\text{H}\)-N/OFQ in HEK\(_{\text{NOP}}\) cells, but was able to displace this radioligand in the co-expression system (pK\(_{i}\): 7.91) (Fig 4 and Table 2) displaying similar affinity when displacing \(^{3}\text{H}\)-DPN in this cell line.

N/OFQ displaced \(^{3}\text{H}\)-N/OFQ in HEK\(_{\text{NOP}}\) cell membranes (pK\(_{i}\): 9.39) and in the HEK\(_{\text{MOP/NOP}}\) co-expression system with a pK\(_{i}\) of 9.11 (Fig 4 and Table 2). N/OFQ was unable to displace \(^{3}\text{H}\)-DPN in HEK\(_{\text{MOP}}\) cell membranes but did displace this radioligand in the co-expression system with a pK\(_{i}\) of 8.75; displaying similar affinity to that achieved in the co-expression system when using \(^{3}\text{H}\)-N/OFQ.

Both the bivalent ligands, DeNo and De101, displayed affinity across all three cell lines. In HEK\(_{\text{MOP}}\) cells, DeNo displaced \(^{3}\text{H}\)-DPN with a pK\(_{i}\) of 9.00, DeNo demonstrated a statistically significant reduction in affinity for the MOP receptor in the co-expression system (pK\(_{i}\): 8.44) (Fig 5 and Table 2). DeNo displaced \(^{3}\text{H}\)-N/OFQ in both HEK\(_{\text{NOP}}\) and HEK\(_{\text{MOP/NOP}}\) cell lines with pK\(_{i}\) values of 9.69 and 9.59 respectively.

When using \(^{3}\text{H}\)-DPN, De101 produced pK\(_{i}\) values of 9.28 and 8.63 for HEK\(_{\text{MOP}}\) and HEK\(_{\text{MOP/NOP}}\) respectively. De101 displaced \(^{3}\text{H}\)-N/OFQ in both HEK\(_{\text{NOP}}\) and HEK\(_{\text{MOP/NOP}}\), with pK\(_{i}\) values of 8.68 and 9.24 respectively (Fig 5 and Table 2).

When using \(^{3}\text{H}\)-DPN in HEK\(_{\text{MOP/NOP}}\) cell membranes, both DeNo (134±6%) and De101 produce displacement maxima in excess of 100% (126±3%; Fig 5), this was statistically

Fig 4. Displacement binding curves of A) Dermorphin in HEK\(_{\text{MOP}}\) and HEK\(_{\text{MOP/NOP}}\) cell membranes against \(^{3}\text{H}\)-DPN or B) in HEK\(_{\text{NOP}}\) and HEK\(_{\text{MOP/NOP}}\) cell membranes against \(^{3}\text{H}\)-N/OFQ. Displacement binding curves of C) N/ OFQ in HEK\(_{\text{MOP}}\) and HEK\(_{\text{MOP/NOP}}\) cell membranes against \(^{3}\text{H}\)-DPN or D) in HEK\(_{\text{NOP}}\) and HEK\(_{\text{MOP/NOP}}\) cell membranes against \(^{3}\text{H}\)-N/OFQ. Data are the mean (±SEM) of n = 5 experiments.

https://doi.org/10.1371/journal.pone.0260880.g004
Table 2. The pKᵢ values for Dermorphin, N/OFQ, DeNO and De101 in HEK<sub>MOP</sub>, HEK<sub>NOP</sub> and HEK<sub>MOP/NOP</sub>.

|                     | HEK<sub>MOP</sub>   | HEK<sub>NOP</sub> | HEK<sub>MOP/NOP</sub> | HEK<sub>MOP/NOP</sub> |
|---------------------|---------------------|-------------------|------------------------|------------------------|
| [*H*]-DPN           | 8.32 (±0.15)        | No Binding        | 7.86 (±0.14)           | 7.91 (±0.22)           |
| N/OFQ               | No Binding          | 9.39 (±0.07)      | 8.75 (±0.03)           | 9.11 (±0.09)           |
| DeNO                | 9.00 (±0.11)        | 9.69 (±0.13)      | 8.44 (±0.16)           | 9.59 (±0.17)           |
| De101               | 9.28 (±0.11)        | 8.68 (±0.08)      | 8.63 (±0.03)           | 9.24 (±0.04)           |

*a* significant difference vs Dermorphin (p<0.05).

*b* significant difference to the reference ligand, N/OFQ, (p<0.05).

*c* significant difference to the reference ligand, Dermorphin, in HEK<sub>MOP/NOP</sub> (p<0.05).

*d* significant difference to the reference ligand, N/OFQ, in HEK<sub>MOP/NOP</sub> (p<0.05). Data are displayed as mean (±SEM) of n = 5 experiments. p≤0.05 (ANOVA) followed by post hoc Bonferroni multiple comparisons.

https://doi.org/10.1371/journal.pone.0260880.t002

![Fig 5. Displacement binding curves of A) DeNo in HEK<sub>MOP</sub> and HEK<sub>MOP/NOP</sub> cell membranes against [*H*]-DPN or B) in HEK<sub>NOP</sub> and HEK<sub>MOP/NOP</sub> cell membranes against [*H*]-N/OFQ. Displacement binding curves of C) De101 in HEK<sub>MOP</sub> and HEK<sub>MOP/NOP</sub> cell membranes against [*H*]-DPN or D) in HEK<sub>NOP</sub> and HEK<sub>MOP/NOP</sub> cell membranes against [*H*]-N/OFQ. Data are the mean (±SEM) of n = 5 experiments.](https://doi.org/10.1371/journal.pone.0260880.g005)
significant compared to Dermorphin in HEK\textsubscript{MOP/NOP} cells ($p<0.05$). This effect is not seen for these ligands in either of the single expression systems.

Collectively these data show that in the double expression system N/OFQ is able to displace $[^3\text{H}]$-DPN and Dermorphin is able to displace $[^3\text{H}]$-N/OFQ, further suggesting receptor interaction.

**Confocal microscopy.** Co-localisation of MOP and NOP was determined through co-incubation with N/OFQ\textsubscript{ATTO594} (NOP) and Dermorphin\textsubscript{ATTO488} (MOP) (Fig 6A–6C). In HEK\textsubscript{MOP/NOP} cells, binding of Dermorphin\textsubscript{ATTO488} and N/OFQ\textsubscript{ATTO594} was co-localized with a Pearson correlation coefficient of 0.91 suggesting that the two ligands, and hence receptors, were in close proximity to each other. Binding of N/OFQ\textsubscript{ATTO594} in HEK\textsubscript{MOP/NOP} was reversed in the presence of 10 μM SB-612111, but not the MOP antagonist Naloxone (10μM) (Fig 6D and 6E). Binding of Derm\textsubscript{ATTO488} was reversed in the presence of 10 μM Naloxone in HEK-MOP/NOP, but not 10 μM SB-612111 (Fig 6F and 6G).

In order to assess the potential for receptor interaction in non-recombinant systems, hippocampal (CA1) slices from mouse brain were incubated with 100 nM each of Dermorphin\textsubscript{ATTO488} and N/OFQ\textsubscript{ATTO594} (Fig 6H–6K). Hippocampal slice tissue opioid receptor mRNA

---

**Fig 6.** 100nM of Derm\textsubscript{ATTO488} (A) and 100nM N/OFQ\textsubscript{ATTO594} (B) were co-incubated in HEK\textsubscript{MOP/NOP} cells at 4°C, with both ligands binding to the cell surface. Image (C) demonstrates significant co-localisation (Pearson coefficient = 0.91). 100nM of Derm\textsubscript{ATTO488} and 100nM of N/OFQ\textsubscript{ATTO594} were added to HEK\textsubscript{MOP/NOP} cells preincubated with 10μM naloxone and demonstrated binding of N/OFQ\textsubscript{ATTO594} (D) but not Derm\textsubscript{ATTO488} (E). 100nM of Derm\textsubscript{ATTO488} and 100nM of N/OFQ\textsubscript{ATTO594} were added to HEK\textsubscript{MOP/NOP} cells preincubated with 10μM SB-612111 and demonstrated binding of Derm\textsubscript{ATTO488} (F) but not N/OFQ\textsubscript{ATTO594} (G). Mouse CA1 hippocampal cells were seeded onto 25mm glass coverslips, allowed to initiate process extension. Cells were treated with Ab-Delivirin ™ coated NeuN-lexaflour\textsuperscript{405} antibodies (Blue stained nucleus). Mouse hippocampal CA1 cells (H) were co-treated with 100nM each of Derm\textsubscript{ATTO488} (I) and N/OFQ\textsubscript{ATTO594} (J). The composite image (K) demonstrates significant co-localisation (Pearson coefficient = 0.83). In order to determine selectivity in mouse hippocampal CA1 tissue, a series of controls were undertaken in the presence of MOP (CTOP) and NOP (SB-612111) antagonists. In the presence of 10 μM SB-612111, 100nM Derm\textsubscript{ATTO488} (L) bound to CA1 hippocampal cells, while the binding of N/OFQ\textsubscript{ATTO594} was inhibited (N). 100nM Derm\textsubscript{ATTO488} failed to bind to CA1 hippocampal cells after pretreatment with 10μM CTOP (O), however 100nM N/OFQ\textsubscript{ATTO594} (M) retained binding affinity. All data are representative of 5 separate experiments. Scale bar (white) represents 20μm.
expression profile is shown in S7 Table in S1 File. The anti-NeuN antibody was used to select neuronal processes. Both fluorescent opioid ligands bound in similar regions (Pearson correlation coefficient 0.83), further suggesting receptor interaction in native tissue (Fig 6K). Importantly, binding of DermATTO488 was fully inhibited by 10 μM of the MOP selective antagonist CTOP indicating the probe bound fully to MOP, while CTOP did not inhibit the binding of N/OFQATTO594 (Fig 6M and 6O). Administration of 10 μM of SB-612111 inhibited the binding of N/OFQATTO594, but not DermATTO488, again demonstrating selectivity for their respective receptors ex vivo (Fig 6L and 6N).

To further demonstrate the close proximity of MOP and NOP in HEK MOP/NOP cells, FRET experiments were performed using DermATTO488 and N/OFQATTO594 (Fig 7A–7D). DermATTO488 was incubated with HEK MOP/NOP cells (100nM) and fluorescence was measured by 488 nm laser in both green (A) and red (B) filter channels. Fluorescence was detected in the green channel after stimulation by 488 nm laser, but not in the red channel. Subsequently, 100 nM N/OFQATTO594 was added and measured using the 488nm laser which does not activate N/OFQATTO594 alone. Fluorescence was detected in the red channel (Fig 7C), indicating FRET and therefore close proximity (Fig 7D) of DermATTO488 and N/OFQATTO594 and by inference of their receptors. Fig 7E–7M demonstrate the relevant controls to demonstrate FRET.

![Image](https://doi.org/10.1371/journal.pone.0260880.g007)

Fig 7. FRET was used to demonstrate proximity of the fluorescent ligands. (A) 100nM DermATTO488 bound to HEK MOP/NOP cells is activated by 488nm laser and can be measured in the green channel; no fluorescence is demonstrated in the red channel (B). Following the addition of N/OFQATTO594, fluorescence is now detected by FRET in the red channel following stimulation with the 488nm laser (C). There is significant overlap with the green channel (D), shown merged image (DermATTO488 excited by 488nm wavelength, N/OFQATTO594 by 594nm wavelength) demonstrating colocalisation (Pearson Correlation Coefficient = 0.89) further indicating a close proximity between DermATTO488 and N/OFQATTO594. In order to demonstrate FRET-pairing of DermATTO488 and N/OFQATTO594, a series of control experiments were performed. N/OFQATTO594 (100nM) was incubated with HEK MOP/NOP cells and stimulated by 488nm laser (E) and the 594nm laser (F). No fluorescence emission was demonstrated by stimulation with the 488nm laser, while N/OFQATTO594 was activated by the 594nm laser. A further confirmation of FRET pairing is through photobleaching of the acceptor molecule. HEK MOP/NOP cells were co-incubated with 100nM DermATTO488 (G) and N/OFQATTO594 (H) with co-localisation demonstrated in (I). N/OFQATTO594 was exposed to 594nm until loss of fluorescence (i.e. photobleaching) was seen (J). At this point, DermATTO488 fluorescence was measured (K) following which a heatmap (L) was generated, which demonstrated several areas of increased fluorescence (orange). The graph (M) demonstrates levels of fluorescence produced by DermATTO488 in HEK MOP/NOP pre and post photobleaching (p<0.05; student’s t-test). Data are the mean±SEM of five experiment. Scale bar (white) represents 20μm.
**GTPγ[^35]S assays.** Dermorphin stimulated the binding of GTPγ[^35]S in both HEK_{MOP} and HEK_{MOP/NOP} cell lines, with a statistically significant decrease in the pEC_{50} in the co-expression system (Fig 8 and Table 3). N/OFQ stimulated a response in both HEK_{NOP} and HEK_{MOP/NOP} cell lines; in this case there was no significant change in agonist potency. DeNo produced a response in both MOP and NOP single expression and also in the co-expression system. However, pEC_{50} values (pEC_{50}7.63; E_{max}1.26). in the co-expression system were significantly lower than those in both HEK_{MOP} and HEK_{NOP} cell membranes. The value for DeNO was not significantly different from that demonstrated by Dermorphin in HEK_{MOP/NOP}. De101 produced a response in HEK_{MOP} cells but failed to produce a response in HEK_{NOP} cells. De101 produced a pK_{b} of 8.67±10 at 100 nM in antagonist assays when co-incubated with N/OFQ (Fig 10). De101 stimulated binding of GTPγ[^35]S in HEK_{MOP/NOP} cell membranes producing a pEC_{50} of 8.67 and E_{max} of 1.34 (Fig 8 and Table 3). De101 demonstrated a significant increase in pEC_{50} when compared to Dermorphin in the co-expression system. These data seem to indicate that where NOP is stimulated the response to MOP is shifted rightwards.

It has previously been reported that linker length in bivalent pharmacophores can have an effect on receptor binding leading to changes in potency and efficacy. In order to determine whether such effects were occurring in DeNo and De101, Dermorphin and N/OFQ were co-

![Fig 8](https://doi.org/10.1371/journal.pone.0260880.g008)
Table 3. Agonist stimulated GTPγS binding (left) and cyclic AMP inhibition (right-grey) in HEK<sub>MOP</sub>, HEK<sub>NOP</sub> and HEK<sub>MOP/NOP</sub>.

|                | GTPγS<sup>[35]S</sup> | Cyclic AMP |
|----------------|------------------------|------------|
|                | HEK<sub>MOP</sub> | HEK<sub>NOP</sub> | HEK<sub>MOP/NOP</sub> | HEK<sub>NOP</sub> | HEK<sub>MOP/NOP</sub> |
|                | pEC<sub>50</sub> | E<sub>max</sub> | E<sub>max</sub> | pEC<sub>50</sub> | E<sub>max</sub> | pEC<sub>50</sub> | E<sub>max</sub> | pEC<sub>50</sub> | E<sub>max</sub> |
| Dermorphin     | 8.13±0.06           | 1.43±0.03  | No Binding    | 7.60±0.07           | 1.31±0.04  | 8.81±0.06           | 75.99±3.28  | No Activity       | 7.59±0.05           | 81.42±5.49          |
| N/OFQ          | No Binding           |            |              | 8.69±0.13           | 1.47±0.04  | 9.13±0.16           | 1.25±0.05  | No Activity       | 8.72±0.13           | 66.39±0.04          |
| DeNO           | 8.25±0.11           | 1.53±0.03  | 9.24±0.10<sup>b</sup> | 1.47±0.05          | 1.26±0.04  | 8.77±0.19           | 77.30±3.82  | 8.88±0.19           | 67.28±0.05           | 7.55±0.16           | 88.62±13.64          |
| De101          | 8.26±0.11           | 1.44±0.03  | No Activity   | 8.67±0.15           | 1.34±0.05  | 9.00±0.11           | 73.28±2.63  | No Activity       | 8.81±0.12           | 85.99±18.82          |
| Dermorphin & N/OFQ | 7.70±0.29<sup>b</sup> | 1.28±0.03  |              | 8.46±0.14           | 1.33±0.01  |              |              | 8.95±0.17<sup>c</sup> | 84.42±13.30          |
| Dermorphin & UFP-101 | 8.46±0.14 | 1.33±0.01  |              |              |              |              |              |              |

<sup>a</sup> Significant difference between the pEC<sub>50</sub> of DeNO and De101 was found when compared to N/OFQ in HEK<sub>NOP</sub> cells (p<0.05);

<sup>b</sup> Significant difference in potency when compared to the control ligand Dermorphin in HEK<sub>MOP/NOP</sub> (p<0.05).

<sup>c</sup> Significant difference in potency when compared to the control ligand Dermorphin in HEK<sub>MOP/NOP</sub> (p<0.05). Data are displayed as mean (±SEM) of n = 5 experiments. p<0.05 (ANOVA) followed by post hoc Bonferroni multiple comparisons.

https://doi.org/10.1371/journal.pone.0260880.t003

incubated (as individual unlinked peptides) in the co-expression system. This combination of ligands produced a response (pEC<sub>50</sub>7.70; E<sub>max</sub>1.28), which was not significantly different from the pEC<sub>50</sub> for DeNO in the co-expression system, but was significantly different from their respective pEC<sub>50</sub> values in single expression systems (S7A Fig in S1 File and Table 3). Co-incubation of Dermorphin and UFP-101 (pEC<sub>50</sub>8.46; E<sub>max</sub>1.33) produced a response similar to De101 in the co-expression system. These data suggest that linkage per se was unimportant.

**Cyclic Adenosine Monophosphate (cAMP) assay.** cAMP inhibition assays demonstrated a similar trend in function for both the monovalent and bivalent ligands. Dermorphin produced a concentration-dependent inhibition of forskolin-stimulated cAMP formation in HEK<sub>MOP</sub> and HEK<sub>MOP/NOP</sub> whole cells. Dermorphin pEC<sub>50</sub> was significantly reduced in the co-expression system (Table 3 and Fig 9). N/OFQ produced concentration-dependent inhibition of forskolin stimulated cAMP formation in HEK<sub>NOP</sub> and HEK<sub>MOP/NOP</sub> cells. There was no significant difference in the values obtained for N/OFQ in both cell lines (Table 3 and Fig 9).

In HEK<sub>MOP</sub>, HEK<sub>NOP</sub> and HEK<sub>MOP/NOP</sub> cells, DeNO produced a concentration-dependent inhibition of forskolin stimulated cAMP formation. The pEC<sub>50</sub> value obtained by DeNo in HEK<sub>MOP/NOP</sub> cells was significantly lower than both values obtained in HEK<sub>MOP</sub> or HEK<sub>NOP</sub> cells (Table 3 and Fig 9). De101 produced a concentration-dependent inhibition of forskolin stimulated cAMP formation in HEK<sub>MOP</sub> and HEK<sub>MOP/NOP</sub> cells while being inactive in HEK<sub>NOP</sub> Cells. In HEK<sub>MOP/NOP</sub> cells, De101 produced a pEC<sub>50</sub> of 8.81 and E<sub>max</sub> of 85.99%, which was significantly higher than Dermorphin in this cell line. (Table 3 and Fig 9).

Further to the experiments conducted in GTPγS<sup>[35]S</sup> assays to determine whether linkage of pharmacophores could influence activity, Dermorphin and N/OFQ or Dermorphin and UFP-101 were co-administered over a range of concentrations in HEK<sub>MOP/NOP</sub> cells (S7B Fig in S1 File and Table 3). Dermorphin and N/OFQ produced a pEC<sub>50</sub> of 8.04, similar to both Dermorphin alone, or DeNO in the co-expression system but significantly lower than N/OFQ alone in HEK<sub>MOP/NOP</sub> and HEK<sub>NOP</sub> (Table 3). Dermorphin co-administered with UFP-101 produced a pEC<sub>50</sub> of 8.95, which was significantly greater than Dermorphin in the co-expression system, but similar to the potency of Dermorphin in HEK<sub>MOP</sub> cell line (Table 3).

A further demonstration of De101 antagonist activity was measured in the cyclic AMP inhibition assay. In these experiments De101 produced a pK<sub>B</sub> of 8.77 (±0.18) (Fig 10B).
As in GTPγ[35S] assays, in the co-expression system NOP activation led to a rightward shift in the curve of MOP agonists. The results would indicate activation of NOP leads to an inhibitory action on MOP receptor ligand activation when these two receptors are co-expressed.

**ERK1/2 activity.** Dermorphin (1 μM) produced a time-dependent increase in pERK1/2 in both HEK_MOP and HEK_MOP/NOP cells (Fig 11). In HEK_MOP cells this peaked at 10 min (maximum fold phosphorylation 7.21), which subsequently returned to basal levels after 15 min. In HEK_MOP/NOP cells, Dermorphin peaked at 10 minutes (maximum fold phosphorylation 11.82) and remained elevated for the duration of the time course (30 min).

N/OFQ (1 μM) produced a time-dependent increase in pERK1/2 in both HEK_NOP and HEK_MOP/NOP cells (Fig 11). In HEK_NOP cells, N/OFQ produced a biphasic stimulation of ERK1/2 activity which peaked at 5 (3.91 Fold) and 10 min (5.89 fold), and returned to basal after 15 min. In HEK_MOP/NOP cells, N/OFQ-stimulated pERK1/2 activity reached a peak at 7.5–10 min (~5 fold). ERK1/2 activity reduced from 15 min and remained above basal activity for the duration of the time course.

In HEK_MOP, HEK_NOP and HEK_MOP/NOP cells, DeNO (1μM) produced a time-dependent increase in pERK1/2 (Fig 11). In HEK_MOP cells, DeNO produced a slow phosphorylation of ERK1/2 peaking around 10 min (3.65 fold) and remained elevated. In HEK_NOP cells, DeNO

---

Fig 9. A) Dermorphin stimulated inhibition of forskolin-induced cAMP production in HEK_MOP and HEK_MOP/NOP cells. B) N/OFQ stimulated inhibition of forskolin-induced cAMP production in HEK_NOP and HEK_MOP/NOP cells. C) DeNO stimulated inhibition of forskolin-induced cAMP production in HEK_MOP, HEK_NOP and HEK_MOP/NOP cells. D) De101 stimulated inhibition of forskolin-induced cAMP production in HEK_MOP, HEK_NOP and HEK_MOP/NOP cells. Data are the mean (±SEM) for n = 5 experiments.

https://doi.org/10.1371/journal.pone.0260880.g009
produced a biphasic increase at 10 (8.16 fold) and 20 min (10.03 fold). In HEK MOP/NOP cells, the phosphorylation of ERK1/2 was delayed beginning at 15 min and remain elevated at 30 min (11.84 fold).

In HEK MOP and HEK MOP/NOP cells, De101 (1 μM) produced a time-dependent increase in pERK1/2 (Fig 11). In HEK MOP cells, De101 produced a peak phosphorylation of ERK1/2 at 10 min (9.65 fold), followed by a prompt decline to basal. In HEK MOP/NOP cells, the phosphorylation of ERK1/2 was delayed beginning at 20 min (12.59 fold) and remaining elevated at 30 min. De101 did not phosphorylate of ERK1/2 in HEK NOP cells.

Full uncropped blots are available as a supplementary document.

Discussion

We have generated a MOP/NOP co-expression system which we have used to determine (i) how targeting of two opioid receptors affects cellular signalling cascades and (ii) evidence for receptor interaction. Our HEK MOP/NOP expressed similar numbers of NOP (689 fmol/mg protein) and MOP (464 fmol/mg protein) receptors. Similar levels of expression of the two receptors of interest is important such that the potential to create receptor and coupling reserves is equal.

Using our novel fluorescent ligands [14,39], we aimed to determine whether MOP and NOP receptors were expressed in close proximity to each other in our co-expression system. A significant overlap in binding of both fluorescent probes on the HEK MOP/NOP cell surface was detected, producing a Pearson coefficient correlation of 0.91 (High level of colocalization). Furthermore, FRET experiments demonstrate the close proximity of the fluorescent ligands and, by extension, MOP and NOP receptors. For FRET to occur ligands must be within 10 nm of each other [54] thereby indicating that these two receptors are close enough to potentially form a structural interaction [55]. However, this is not a natural system with both receptors expressed due to cloning techniques. In order to demonstrate the potential for co-expression in a native system, we assessed the binding of N/OFQATTO594 and DermATTO488 in ex vivo CA1 hippocampal neuronal processes. The NOP selective antagonist SB-612111 and the MOP-selective antagonist CTOP were used to demonstrate selectivity of binding of the fluorescent ligands in the native system and, fluorescent antibodies to NeuN were used to identify
Fig 11. (A) ERK1/2 phosphorylation in HEK<sub>MOP</sub> cell lines induced by Dermorphin, DeNo and De101. (B) N/OFQ, DeNO and De101 induced ERK1/2 phosphorylation in HEK<sub>NOP</sub>. (C) The induction of ERK1/2 phosphorylation produced by Dermorphin, N/OFQ, DeNo or De101 in HEK<sub>MOP/NOP</sub> cell lines. Right hand panels are representative. In HEK<sub>MOP</sub>, Dermorphin (F<sub>(1,14,4,57)</sub> = 26.59; p<0.0042), DeNO (F<sub>(7,32)</sub> = 8.37; p<0.0001) and De101 (F<sub>(7,32)</sub> = 17.55; p<0.0001) were significant. In HEK<sub>NOP</sub>, N/OFQ (F<sub>(7,32)</sub> = 16.91; p<0.0001) and DeNO (F<sub>(7,32)</sub> = 10.11; p<0.0001) were significant while De101 (F<sub>(7,32)</sub> = 1; p = 0.45) was not. In HEK<sub>MOP/NOP</sub>, Dermorphin (F<sub>(7,32)</sub> = 8.93; p<0.0001), N/OFQ (F<sub>(7,32)</sub> = 7.43; p<0.0001), DeNO (F<sub>(7,32)</sub> = 20.22; p<0.001) and De101 (F<sub>(7,32)</sub> = 19.53; p<0.001) were all significant. *significant increase in activity when compared to basal. p<0.05 (ANOVA) followed by post hoc Bonferroni multiple comparisons. Data are the mean (±SEM) for n = 5 experiments.
neuronal outgrowths. A Pearson coefficient correlation of 0.83 again indicates a high level of co-expression and, therefore, co-expression in the same cell. As a reminder and a note of caution with these experiments; the ligands are both agonists so to prevent internalisation imaging was performed at 4°C and this may limit receptor movement in the membrane. If there is a constitutive interaction then there are no issues but if an interaction is ligand driven low temperature may reduce or slow this interaction. Experiments using other methods to reduce internalisation such as high sucrose could address this issue. Taken as a whole this data provides evidence of MOP/NOP interaction also in native tissue.

Primary pharmacological support for the cellular interaction of MOP and NOP comes from the observation that Dermorphin was able to displace \[^{3}H\]-N/OFQ in the co-expression system, and conversely N/OFQ was able to displace \[^{3}H\]-DPN, characteristics not demonstrated by these ligands in single expression systems. Moreover, all ligands tested demonstrated a loss of affinity at the MOP receptor in the co-expression system.

The ability of high affinity MOP receptor ligands to displace \[^{3}H\]-N/OFQ has been demonstrated previously [34]. However, to the best of our knowledge the effect of NOP ligands on MOP receptor binding has not been previously demonstrated. In this paper, we show that displacement of radioligand binding by MOP or NOP selective ligands (as demonstrated in single receptor systems) is bidirectional in the co-expression system. Both Dermorphin and N/OFQ fail to produce 100% displacement of these respective radioligands in HEK\_MOP/NOP cell membranes. For both DeNo and De101, we demonstrate that these bivalent ligands are able to displace 140% and 120% of \[^{3}H\]-DPN in HEK\_MOP/NOP membranes, which is significantly higher than that of the single pharmacophore ligands. This effect is not seen with in \[^{3}H\]-N/OFQ displacement assays. We have no obvious explanation for this phenomenon but modification of the binding pocket(s) in a potential dimeric conformation might modify the way bivalent ligands interact.

If drugs are to be developed targeting the MOP/NOP heterodimer it is essential to understand any potential changes in downstream signalling. The first pathway investigated in this study was the initial G-protein activation, through measurement of GTP\_\gamma\[^{35}\]S binding. The first evidence for changes in signalling due to direct interaction of MOP and NOP is seen with the peptide Dermorphin, with a loss of potency in the co-expression system when compared to the HEK\_MOP single-expression system. This is comparable with loss of potency seen in DAMGO by Wang and colleagues (2005) in their MOP/NOP co-expression system [35]. There is limited research to determine the effects of co-administration of MOP and NOP ligands, or drugs developed to target both receptors simultaneously, an area this study seeks to address. From the perspective of the NOP receptor, N/OFQ potency increases in the co-expression system. Of more interest is the activity of the bivalent pharmacophore, DeNO. DeNo demonstrates a significant loss of potency when compared to results in both HEK\_MOP and HEK\_NOP. DeNo demonstrated similar potencies to Dermorphin in previous studies, so to determine whether the loss of potency was as a result of cellular interaction of MOP and NOP, Dermorphin and N/OFQ were administered in HEK\_MOP/NOP cells. The results obtained demonstrated a similar potency for Dermorphin in the co-expression system (significantly lower than in single expression system), but also demonstrated a loss of potency for N/OFQ when co-administered with Dermorphin. The MOP agonist-NOP antagonist ligand De101, demonstrated no changes in potency when administered in the co-expression system when compared to single expression systems. Furthermore, the co-administration of Dermorphin and the NOP antagonist UFP-101 produced a potency similar to that produced in HEK\_MOP cells by Dermorphin alone.

The results seen in GTP\_\gamma\[^{35}\]S functional assays were mirrored by those seen in cAMP assays. Dermorphin, DeNO and a combination of Dermorphin and N/OFQ all demonstrated
a reduction in potency in HEK\textsubscript{MOP/NOP} cells. N/OFQ, administered alone, produced a higher potency in the co-expression system, while De101 demonstrated unchanged potency values in the co-expression system when compared to HEK\textsubscript{MOP}. These results further support the suggestion of a MOP/NOP heterodimer that, when formed, leads to changes in signalling.

The final signalling pathway investigated was the ERK1/2 MAPK pathway, activated by both canonical (G-protein) and non-canonical signalling (Arrestin) pathways. The ERK1/2 pathway is involved in numerous cellular functions including proliferation, transcription activation and cell death, all of which are controlled by spatio-temporal activation of the protein itself, with activation at MOP beginning around 2–5 minutes post drug administration peaking from 7.5–10 minutes post administration [56]. The bivalent pharmacophores, DeNo and De101, both demonstrated a significant delay in activation of ERK1/2 in the HEK\textsubscript{MOP/NOP} line when compared to Dermorphin and N/OFQ. More interestingly, the peak activation of ERK1/2 by DeNO occurred at the latest time point in our study. The results again suggest the interaction of MOP and NOP may lead to significant changes in opioid ligand signalling, whether this be through structural interaction or changes in recruitment of G-protein receptor kinase (GRK) and arrestin requires further investigation. As previously demonstrated by Hawes and colleagues, both NOP and MOP activate MAPK via \(G_i\) beta/gamma. Moreover, in CHO cells expressing both receptors pre-treatment with N/OFQ reduced NOP and MOP activation (with DAMGO) of MAPK. These data indicate NOP is modulating MOP signalling [57].

While we provide strong evidence (structural and functional) for direct interaction between MOP and NOP, we cannot confirm heterodimerisation. The overall effect of targeting both MOP and NOP simultaneously appears to be negative with respect to MOP. An important question arising from these findings is does this negative effect carry forward to physiological action with regards to analgesia? The results provided by mixed MOP/NOP agonists such as buprenorphine [16] and cebranopadol [17] would suggest that the overall effect is beneficial, as these drugs display analgesia with reduced side-effects. That said this may be due to targeting MOP and NOP on different cells/pathways or on the same cell if structural receptor interaction is a driver. Future work could include disruption of the heterodimer using single transmembrane domains such as the example used by He and colleagues, whereby the introduction of MOR\textsuperscript{TM1}-TAT lead to the disruption of the MOP-DOP heterodimer [58].

There are several potential limitations to our work probing MOP and NOP interactions. Firstly, the use of transfected cells which can produce significantly higher numbers of receptors than seen native tissue; we have tried to control for this by selecting clones with similar levels of expression for MOP and NOP in single expression systems and both MOP/NOP in the double expression system. Expression differences/overexpression could lead to ‘forced’ interactions between the receptors, to manifest as co-localisation or changes in signalling pathways due to receptor competition for G proteins and or GRKs. In order to assess whether the close proximity of MOP and NOP is due simply to high expression, we extended our study to include co-expression in native tissue and provide significant evidence that interaction of the type seen in recombinants also occurs in a native tissue; mouse hippocampal neurites. Secondly, signalling differences seen in the co-expression system such as reduction in MOP agonist potency may be due to either competition at downstream signalling pathways or, due to the decrease in receptor expression of MOP in the co-expression system when compared to single expression system, a lack of receptor reserves (this could potentially be probed for MOP with \(\beta\)-funtaltrexamine) and therefore decreased potency. We believe this is not the case, as both De101 and dermorphin co-incubated with UFP-101 demonstrate similar or higher potency to the single expression MOP system. If receptor competition for downstream signalling pathways was occurring, this reversal would only be possible if UFP-101 was acting as an inverse agonist, for which we have no evidence.
What does this data mean for development of bivalent opioids and, by extension, bifunctional opioids? Work with cebranopadol and other mixed opioids is now maturing and, in general, these produce good analgesia with reduced side effects. MOP-morphine like molecules are currently seen as the ‘enemy’; driven by the opioid epidemic. That said MOP analgesia and analgesics used in the right setting is/are good [59]. Attempts to design out the troublesome side effect profile have been met with variable success so a different approach with mixed ligands is worthy of consideration. A mixed ligand (bivalent or bifunctional) can potentially reduce the ‘amount’ of MOP activation by adding in NOP (or other targets) with the NOP component producing analgesia in its own right along with reducing the adverse effects of MOP. There is an excellent study in non-human primates from Ko and Naughton [24] showing that largely ineffective doses of i.t morphine and N/OFQ synergise to produce good quality antinociception. Add into the mix partial agonists/biased agonists (for example oliceridine) and allosteric modulators and the potential for analgesic design increases [60,61].

Supporting information
S1 File.
(DOCX)
S1 Raw images.
(PDF)

Acknowledgments
We thank the Advanced Imaging Facility (RRID:SCR_020967); in particular Dr K Straatman, at the University of Leicester for support.

Author Contributions
Conceptualization: R. Guerrini, G. Caló, D. G. Lambert.
Formal analysis: M. F. Bird, J. McDonald, B. Horley, J. P. O’Doherty, B. Fraser, D. G. Lambert.
Funding acquisition: C. L. Gibson, D. G. Lambert.
Investigation: M. F. Bird, J. McDonald, B. Horley, J. P. O’Doherty, B. Fraser.
Methodology: M. F. Bird, J. McDonald, B. Horley, J. P. O’Doherty, B. Fraser, R. Guerrini, G. Caló.
Project administration: C. L. Gibson, D. G. Lambert.
Resources: R. Guerrini, G. Caló.
Supervision: C. L. Gibson, D. G. Lambert.
Writing – original draft: M. F. Bird, J. McDonald, B. Horley, J. P. O’Doherty, B. Fraser, C. L. Gibson, R. Guerrini, G. Caló, D. G. Lambert.
Writing – review & editing: M. F. Bird, J. McDonald, B. Horley, J. P. O’Doherty, B. Fraser, C. L. Gibson, R. Guerrini, G. Caló, D. G. Lambert.
References

1. Toll L. The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders. Current pharmaceutical design. 2013; 19(42):7451–60. PMID: 23448477

2. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockade of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. Journal of Pharmacology and Experimental Therapeutics. 1991; 258(1):299–303. PMID: 1649297

3. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar J, Devi L. A role for heterodimerization of μ and δ opioid receptors in enhancing morphine analgesia. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(14):5135–9. https://doi.org/10.1073/pnas.0307601101 PMID: 15044695

4. Jordan BA, Devi L. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 1999; 399(6737):697–700. https://doi.org/10.1038/21441 PMID: 10385123

5. Pasternak GW, Pan Y-X. Mix and Match: Heterodimers and Opioid Tolerance. Neuron. 2011; 69(1):6–8. https://doi.org/10.1016/j.neuron.2010.12.030 PMID: 21318174

6. Decaillot FM, Rozenfeld R, Gupta A, Devi L. Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A. 2008; 105(41):16045–50. https://doi.org/10.1073/pnas. 0804106105 PMID: 18936969

7. Fujita W, Gomes I, Devi L. Heteromers of mu-delta opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol. 2015; 172(2):375–87. https://doi.org/10.1111/bph.12663 PMID: 24571499

8. Gomes I, Jordan B, Gupta A, Trapaidze N, Nagy V, Devi L. Heterodimerization of μ and δ opioid receptors: a role in opiate synergy. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2000; 20(22):RC110. https://doi.org/10.1523/JNEUROSCI.20-22-j0007.2000 PMID: 11069979

9. Hasbi A, Nguyen T, Fan T, Cheng R, Rashid A, Aljanariam M, et al. Trafficking of Preassembled Opioid μ-δ Heterooligomer–Gz Signaling Complexes to the Plasma Membrane: Coregulation by Agonists. Biochemistry. 2007; 46(45):12997–3009. https://doi.org/10.1021/bi701436w PMID: 17941650

10. He L, Fong J, von Zastrow M, Whistler JL. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell. 2002; 108(2):271–82. https://doi.org/10.1016/s0092-8674(02) 00613-x PMID: 11832216

11. Lee C, Ho I-K. Pharmacological Profiles of Oligomerized μ-Opioid Receptors. Cells. 2013; 2(4):689–714. https://doi.org/10.3390/cells2040689 PMID: 24709876

12. Olson KM, Keresztes A, Tashiro JK, Daconta LV, Hruby VJ, Streicher JM. Synthesis and Evaluation of a Novel Bivalent Selective Antagonist for the Mu-Delta Opioid Receptor Heterodimer that Reduces Morphine Withdrawal in Mice. J Med Chem. 2018; 61(14):6075–86. https://doi.org/10.1021/acs.jmedchem. 8b00403 PMID: 29937476

13. Faouzi A, Uprey R, Gomes I, Massaly N, Keresztes Al, Le Rouziez V, et al. Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template. J Med Chem. 2020; 63(22):13618–37. https://doi.org/10.1021/acs.jmedchem.0c00901 PMID: 33170887

14. Bird M, Guerini R, Calò G, Lambot D. Development and characterisation of a novel fluorescent NOP ligand–N/OFQATTO. British Journal of Anaesthes ia. 2018; 120(5):e6–e7.

15. Bird MF, Cerlesi MC, Brown M, Mallacini D, Vezzi V, Molinari P, et al. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). PLoS One. 2016; 11(6):e0156897. https://doi.org/10.1371/journal.pone.0156897 PMID: 27272042

16. Cremers C, Gruley E, Kyle D, Ko M-C. Roles of Mu Opioid Receptors and Nociceptin/Orphanin FQ Peptide Receptors in Buprenorphine-Induced Physiological Responses in Primates. Journal of Pharmacology and Experimental Therapeutics. 2012. https://doi.org/10.1124/jpet.112.194308 PMID: 22743574

17. Linz K, Christoph T, Tschenchte TM, Koch T, Schiene K, Gautrois M, et al. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. The Journal of pharmacology and experimental therapeutics. 2014; 349(3):535–48. https://doi.org/10.1124/jpet.114.213694 PMID: 24713140

18. Mogil JS, Pasternak GW. The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family. Pharmacological Reviews. 2001; 53(3):381–415. PMID: 11546835

19. Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov. 2008; 7(8):694–710. https://doi.org/10.1038/nrd2572 PMID: 18670432

20. Ding H, Hayashida K, Suto T, Sukhtankar DD, Kimura M, Mendenhall V, et al. Supraspinally actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates. Br J Pharmacol. 2015; 172(13):3302–12. https://doi.org/10.1111/bph.13124 PMID: 25723260
21. Meunier JC, Mollerau C, Toll L, Suauadeau C, Moisand C, Alvinerie P, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995; 377(6549):532–5. https://doi.org/10.1038/377532a0 PMID: 7566152

22. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995; 270(5237):792–4. https://doi.org/10.1126/science.270.5237.792 PMID: 7481766

23. Schroder W, Lambert DG, Ko MC, Koch T. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol. 2014; 171(16):3777–800. https://doi.org/10.1111/bph.12744 PMID: 24762001

24. Ko M-C, Naughton NN. Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. The journal of pain. 2009; 10(5):509–16. https://doi.org/10.1016/j.jpain.2008.11.006 PMID: 19213294

25. Ding H, Czoty PW, Kiguchi N, Cai-Kopeci G, Sukhtankar DD, Nader MA, et al. A novel orvinol analog, BU08026, as a safe opioid analgesic without abuse liability in primates. Proceedings of the National Academy of Sciences. 2016; 113(37):E5511–E8. https://doi.org/10.1073/pnas.1605295113 PMID: 27573832

26. Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, et al. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med. 2018; 10(456). https://doi.org/10.1126/scitranslmed.aar3483 PMID: 30158150

27. Christoph A, Eerdekes MH, Kok M, Volkers G, Freynhagen R. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain. 2017; 158(9):1813–24. https://doi.org/10.1097/j.pain.0000000000000986 PMID: 28644196

28. Calo G, Lambert DG. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic. British Journal of Anaesthesia. 2018; 121(5):1105–14. https://doi.org/10.1016/j.bja.2018.06.024 PMID: 30336855

29. Lambert DG. Mixed mu-nociceptin/orphanin FQ opioid receptor agonists and the search for the analgesic holy grail. Br J Anaesth. 2019; 122(6):e95–e7. https://doi.org/10.1016/j.bja.2019.02.022 PMID: 30961914

30. Houtani T, Nishi M, Takeshima H, Sato K, Sakuma S, Kakimoto S, et al. Distribution of nociceptin/orphanin FQ precursor protein and receptor in brain and spinal cord: a study using in situ hybridization and X-gal histochemistry in receptor-deficient mice. The Journal of comparative neurology. 2000; 424(3):489–508. PMID: 10906715

31. Pan Z, Hirakawa N, Fields HL. A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron. 2000; 26(2):515–22. https://doi.org/10.1016/s0896-6273(00)81183-6 PMID: 10839369

32. Vaughan CW, Connor M, Jennings EA, Marinelli S, Allen RG, Christie MJ. Actions of nociceptin/orphinin FQ and other prepronociceptin products on rat rostral ventromedial medulla neurons in vitro. The Journal of physiology. 2001; 534(Pt 3):489–59. https://doi.org/10.1111/j.1469-7793.2001.00849.x PMID: 11483714

33. Evans RM, You H, Hamed S, Altier C, Mezghani A, Bourinet E, et al. Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. The Journal of biological chemistry. 2010; 285(2):1032–40. https://doi.org/10.1074/jbc.M109.046364 PMID: 19987453

34. Pan YX, Bolan E, Pasternak GW. Dimerization of morphine and orphanin FQ/nociceptin receptors: generation of a novel opioid receptor subtype. Biochem Biophys Res Commun. 2002; 297(3):659–63. https://doi.org/10.1016/s0006-291x(02)02258-1 PMID: 12270145

35. Wang HL, Hsu CY, Huang PC, Kuo YL, Li AH, Yeh TH, et al. Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro opioid receptor agonist. J Neurochem. 2005; 92(6):1285–94. https://doi.org/10.1111/j.1471-4159.2004.02921.x PMID: 15748148

36. Majumdar S, Grinell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, et al. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci U S A. 2011; 108(49):19778–83. https://doi.org/10.1073/pnas.1111523110 PMID: 22106286

37. Calo G, Guerrini R, Rizzi A, Salvadori S, Burmeister M, Kapusta DR, et al. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS drug reviews. 2005; 11(2):97–112. https://doi.org/10.1111/j.1527-3458.2005.tb00264.x PMID: 16007234

38. McDonald J, Calo G, Guerrini R, Lambert DG. UFP-101, a high affinity antagonist for the nociceptin/ orphanin FQ receptor: radioligand and GTPgamma(S) binding studies. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367(2):183–7. https://doi.org/10.1007/s00210-002-0661-8 PMID: 12595960

39. Giakomidi D, Bird MF, McDonald J, Marzola E, Guerrini R, Chanoch S, et al. Evaluation of [Cys(ATT0488)]Dermorphin-NH2 as a novel tool for the study of μ-opioid peptide receptors. PLoS One. 2021; 16(4):e0250011. https://doi.org/10.1371/journal.pone.0250011 PMID: 33891604
40. Nam MH, Han KS, Lee J, Bae JY, An H, Park S, et al. Expression of μ-Opioid Receptor in CA1 Hippocampal Astrocytes. Exp Neurobiol. 2018; 27(2):120–8. https://doi.org/10.5607/en.2018.27.2.120 PMID: 29731678

41. Higgins GA, Kew JN, Richards JG, Takeshima H, Jenck F, Adam G, et al. A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory. The European journal of neuroscience. 2002; 15(5):911–22. https://doi.org/10.1046/j.1460-9568.2002.01926.x PMID: 11906533

42. Koga S, Onishi H, Masuda S, Fujimura A, Ichimiy a S, Nakayama K, et al. PTPN3 is a potential target for lung neuroendocrine tumor. Transl Oncol. 2021; 14(9):101152. https://doi.org/10.1016/j.tranon.2021.101152 PMID: 34134073

43. Garcia-Garcia S, Rodrigo-Faus M, Fonseca N, Manzano S, Gyöﬀty B, Ocaña A, et al. HGK promotes metastatic dissemination in prostate cancer. Sci Rep. 2021; 11(1):12287. https://doi.org/10.1038/s41598-021-91292-2 PMID: 34112843

44. Qiao X, Zhu Y, Dang W, Wang R, Sun M, Chen Y, et al. Dual-specificity phosphatase 15 (DUSP15) in the nucleus accumbens is a novel negative regulator of morphine-associated contextual memory. Addict Biol. 2021; 26(1):e12884. https://doi.org/10.1111/adb.12884 PMID: 32043707

45. Kim H, Park J, Kang H, Yun SP, Lee YS, Lee YI, et al. Activation of the Akt1-CREB pathway promotes RNF146 expression to inhibit PARP1-mediated neuronal death. Science signaling. 2020; 13(663). https://doi.org/10.1126/scisignal.aax7119 PMID: 33443209

46. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin reagent. Journal of biological chemistry. 1951; 193(1):265–75.

47. Kitayama M, McDonald J, Barnes TA, Calo G, Guerrini R, Rowbotham DJ, et al. In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue cCys(7,10)N/OFQ(1–13)NH2. Naunyn Schmiedebers Arch Pharmacol. 2007; 375(6):369–76. https://doi.org/10.1007/s00210-007-0170-x PMID: 17598088

48. Akram A, Gibson CL, Grubb BD. Neuroprotection mediated by the EP3 receptor avoids the detrimental side effects of COX-2 inhibitors following ischaemic injury. Neuropharmacology. 2013; 65:165–72. https://doi.org/10.1016/j.neuropharm.2012.09.010 PMID: 23041537

49. Wallrabe H, Elangovan M, Burchard A, Periasamy A, Barroso M. Confocal FRET microscopy to measure clustering of ligand-receptor complexes in endocytic membranes. Biophys J. 2003; 85(1):559–71. https://doi.org/10.1016/S0006-2952(03)74500-7 PMID: 12829510

50. Snapp EL, Hegde RS. Rational design and evaluation of FRET experiments to measure protein proximities in cells. Curr Protoc Cell Biol. 2006; Chapter 17:Unit 17 9. https://doi.org/10.1002/0471143030.cb1709s32 PMID: 18228480

51. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099–108. https://doi.org/10.1016/0006-2952(73)90196-2 PMID: 4202581

52. Stauffer W, Sheng H, Lim HN. EzColocalization: An ImageJ plugin for visualizing and measuring colocalization in cells and organisms. Scientific reports. 2018; 8(1):15764-. https://doi.org/10.1038/s41598-018-35592-8 PMID: 30361629

53. Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T, Castro A. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci U S A. 2010; 107(28):12564–9. https://doi.org/10.1073/pnas.0914191107 PMID: 20538976

54. Vogel SS, van der Meer BW, Blank PS. Estimating the distance separating fluorescent protein FRET pairs. Methods. 2014; 66(2):131–8. https://doi.org/10.1016/j.ymeth.2013.06.021 PMID: 23811334

55. Del Piccolo N, Sarabiouf P, Hristova K. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. The Journal of biological chemistry. 2017; 292(4):1288–301. https://doi.org/10.1074/jbc.M116.755777 PMID: 27927983

56. Duraffour C, Kumala E, Anselmi L, Brecha NC, Sternini C. Opioid-Induced Mitogen-Activated Protein Kinase Signaling in Rat Enteric Neurons following Chronic Morphine Treatment. PLOS ONE. 2014; 9(10):e110230. https://doi.org/10.1371/journal.pone.0110230 PMID: 25302800

57. Hawes BE, Fried S, Yao X, Weig B, Graziano MP. Nociceptin (ORL-1) and μ-Opioid Receptors Mediate Mitogen-Activated Protein Kinase Activation in CHO Cells Through a Gi-Coupled Signaling Pathway: Evidence for Distinct Mechanisms of Agonist-Mediated Desensitization. Journal of Neurochemistry. 1998; 71(3):1024–33. https://doi.org/10.1046/j.1471-4159.1998.71031024.x PMID: 9721727

58. He S-Q, Zhang Z-N, Guan J-S, Liu H-R, Zhao B, Wang H-B, et al. Facilitation of μ-Opioid Receptor Activity by Preventing δ-Opioid Receptor-Mediated Codegradation. Neuron. 2011; 69(1):120–31. https://doi.org/10.1016/j.neuron.2010.12.001 PMID: 21220103
59. Hemmings HC, Lambert DG. The good, the bad, and the ugly: the many faces of opioids. British Journal of Anaesthesia. 2019; 122(6):705–7. https://doi.org/10.1016/j.bja.2019.04.003 PMID: 31005244

60. Lambert D, Calo G. Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults. British journal of anaesthesia. 2020; 125(6):e473–e4. https://doi.org/10.1016/j.bja.2020.09.021 PMID: 33070948

61. Burford NT, Traynor JR, Alt A. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Br J Pharmacol. 2015; 172(2):277–86. https://doi.org/10.1111/bph.12599 PMID: 24460691